Jade Biosciences Inc (JBIO) — Smart Money Tracker (13F, Q2 2026)

JBIO ranks #3545 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

JBIO is a top-conviction position for Versant Venture Management, LLC — at 13.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in JBIO belongs to FMR LLC, but the position matters far more to Versant Venture Management, LLC, who has 13.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Ken Griffin has added to its JBIO position for two straight quarters, increasing it by $20.1M to reach $20.7M today.

Steve Cohen has trimmed its JBIO position for two straight quarters, cutting it by $4.9M while still holding $3.7M.

JBIO is up 2.5% today, and institutions have been net buyers of $531.9M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

JBIO reported a net loss of $127.4M in its latest fiscal year.

• Not yet profitable — net loss of $127.4M in the latest fiscal year
• Operating cash flow was negative, using $94.7M in cash
• Current ratio of 21.09x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.05x equity — within a conventional range